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Abstract
Background: Genetic alterations, including the overexpression of epidermal growth factor receptor (EGFR), play a
crucial role in ovarian carcinogenesis. To date, EGFR targeting has shown limited antitumor effects in ovarian cancer
when administered as monotherapy. We previously identified platelet-activating factor receptor (PAFR) as being
overexpressed in ovarian cancer and found that its ligand PAF evoked EGFR phosphorylation. To determine whether
PAFR targeting can enhance the antitumor efficacy of EGFR inhibition, we investigated the effects of a PAFR antagonist
(WEB2086) in conjunction with an EGFR inhibitor (AG1478).
Methods: The expression of EGFR and PAFR in CAOV-3 and SKOV-3 ovarian cancer cell lines was measured by Western
blot and immunocytochemistry. Synergy was determined using isobologram analysis. The effects of combined PAFR
and EGFR targeting on both cells were assessed by using CCK-8, transwell, flow cytometry, western blot analysis. In vivo
studies were conducted using CAOV-3 cells xenografted in nu/nu mice.
Results: Treatment with combination WEB2086 and AG1478 resulted in significantly greater inhibition of proliferation
and invasion compared to either drug alone. When examining equipotent combinations of WEB2086 and AG1478
to determine potential synergy, a combination index (CI) of 0.49 was identified for CAOV-3 cells and a CI of 0.58
for SKOV-3 cells indicating synergy. This co-inhibition induced significantly more apoptosis and arrested the cells
at G0/G1 phase in both cell lines. The activation of PAFR and/or EGFR induced phosphorylation of the mTOR,
AKT, and MAPK pathways. Combined PAFR and EGFR targeting synergistically diminished the expression of PAFR
and EGFR phosphorylation and downstream signaling. In vivo studies further verified the antitumor effects of
combined PAFR and EGFR targeting in a CAOV-3 xenograft model.
Conclusions: These results suggest that WEB2086 and AG1478 are synergistic in ovarian cancer cells with high
expression of both PAFR and EGFR. The presented approach may have important therapeutic implications in the
treatment of ovarian cancer patients.
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Ovarian cancer is the fifth most common cause of death
from all cancers among women in the world and has the
highest mortality rate of gynecological cancers [1]. Overall,
ovarian cancer has the worst prognosis of all gynecological
cancers, with a 5-year survival rate of less than 40% [2].
Surgical resection and platinum-based combination regi-
mens offer a modest but significant survival advantage in
ovarian cancer patients with advanced or metastatic dis-
ease, though most patients eventually experience disease
progression. Advances in the understanding of the mo-
lecular biology of cancer have enabled the discovery of
several potential molecular targets and the development
of novel targeted therapies.
Epidermal growth factor receptor (EGFR) is involved in
the development and progression of several human can-
cers, including ovarian cancer. The most common type of
ovarian cancer arises from ovarian surface epithelium, tis-
sue that commonly expresses EGFR [3]. Approximately
70% of ovarian tumors express activated EGFR [4]. EGFR
is a transmembrane receptor that plays a significant role
in neural development and the formation of skin. EGFR
also plays a role in various pro-survival and anti-apoptotic
pathways in cancer cells [5-7]. Furthermore, EGFR is also
involved in cell migration, metastasis, angiogenesis, and
the epithelial mesenchymal transition (EMT) [8-10]. How-
ever, recent clinical trials targeting EGFR with cetuximab
[11-13], matuzumab [14,15], gefitinib [16], and erlotinib
[17,18] in epithelial ovarian cancer patients have shown
only modest clinical responsiveness. The modest re-
sponses of EGFR blockade when monoclonal antibodies
or tyrosine kinase inhibitors are administered as single
agents could be attributed to compensation by other sig-
naling pathways [19].
Various ligands such as epidermal growth factor (EGF)
and transforming growth factor (TGF) can activate EGFR.
Our previous studies have demonstrated that platelet-
activating factor (PAF) also induced increased EGFR
phosphorylation [20]. PAF is one of major phospholipid
mediators functioning in many different biological path-
ways in inflammatory diseases and cancers. PAF induces di-
verse biological effects through its specific receptor, PAFR,
which belongs to the G-protein coupled receptor (GPCR)
family [21-23]. We have demonstrated that the PAFR gene
and protein are overexpressed in ovarian cancer tissues and
cells and that PAF can promote the proliferation and inva-
sion of ovarian cancer cells in a PAFR-dependent manner.
These results suggest that activated EGFR and PAFR may
synergistically promote the progression of ovarian cancer
and that the constitutive activation of EGFR and down-
stream signaling pathways by PAFR may contribute to the
inefficacy of EGFR inhibitors in ovarian cancer.
The aim of the present work was to determine
whether the addition of PAFR targeting can enhance the
antitumor efficacy of EGFR tyrosine kinase inhibitors.
The PAFR antagonist WEB2086 was combined with the
EGFR inhibitor AG1478 in ovarian cancer in vitro and
in vivo. The effects of the two agents, alone and in com-
bination, were determined in vitro and in vivo and the
underlying molecular mechanisms were assessed.
Materials and methods
Cell culture and chemical reagents
The ovarian cancer cell lines CAOV-3 and SKOV-3
(purchased from the Cell Bank of the Chinese Academy
of Science, Shanghai, China) were cultured at 37°C in a
humidified 5% CO2 atmosphere in RPMI-1640 medium
with 10% fetal calf serum (Gibco, Invitrogen, Carlsbad,
CA), 100 IU/ml penicillin G, and 100 mg/ml strepto-
mycin sulfate (Sigma-Aldrich, St. Louis, MO). AG1478
(EGFR inhibitor) [24] and WEB2086 (PAFR antagonist)
[25] were purchased from Sigma-Aldrich (St Louis, MO). A
Cell Counting Kit 8 (CCK8) was purchased from Dojindo
Molecular Technologies, Inc. (Kumamoto, Japan), and the
Alexa Fluor 488 annexin V/Dead Cell Apoptosis Kit was
obtained Invitrogen (Carlsbad, CA). Rabbit polyclonal
antibodies directed against PAFR, cleaved-caspase3,
cleaved-PARP, phospho/total- EGFR, phospho/total- β-
arrestin2, phospho/total- P70S6K, phospho/total- AKT,
phospho/total- 4EBP1, and phospho/total- ERK were
used in this study. All of these antibodies were pur-
chased from Cell Signaling Technology Co. Mouse
monoclonal antibodies directed against actin were also
used (Sigma, Missouri, USA).
Western blot analysis
Cellular extracts were prepared in modified radioimmu-
noprecipitation assay (RIPA) buffer (50 mM Tris–HCl
pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM
NaCl, 1 mM EDTA, 1 mM PMSF, and protease inhibitor
cocktail). The protein concentrations of the cellular ex-
tracts were measured using a Bio-Rad protein assay kit.
The cellular extracts were subjected to SDS-PAGE, and
the proteins were transferred to PVDF membranes. After
blocking for 1 h at room temperature in 5% BSA, the
blots were probed with the primary antibody at a 1:1000
dilution and incubated overnight at 4°C. Subsequently,
the blots were washed three times and incubated for 1 h
at room temperature with a 1:10000 dilution of the sec-
ondary peroxidase-conjugated antibodies. Following three
washes, the immunoreactive bands were detected using
electrochemiluminescence (ECL).
Immunocytochemistry
Immunocytochemistry was used to detect the expression
of EGFR and PAFR. After fixation with 4% paraformal-
dehyde, cells were incubated with an anti-EGFR (1:50)
or -PAFR (1:50) antibody overnight, and then incubated
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The staining reaction was performed with diaminobenzi-
dine. The cells were counter-stained with hematoxylin
to detect nuclei, and imaged using light microscopy
(Olympus, Tokyo, Japan).
Cell proliferation and invasion assay
Cells were seeded in 96-well plates and treated with dif-
ferent doses of WEB2086, AG1478, or both for 72 hours.
Cell proliferation was measured with the CCK-8 assay. A
10-μL aliquot of CCK-8 solution was added to 100 μL
medium in each well for 1–4 hours, and the absorbance
was measured at 450 nm. The percentage of cell viability
was determined relative to the control. Each experiment
was performed in six replicate wells for each drug con-
centration. The IC50 values were calculated with the
SPSS software using the bliss method.
Cell invasion activity assay were conducted with an
8 μm matrigel invasion chamber (Corning, NY). Experi-
ments were carried out according to the manufacture’s
protocal. Briefly, each well insert was coated with 100 μl
mixture matrigel: serum-free medium, followed by incuba-
tion at 37°C for 4 hours. Cells were then trypsin digested
and transferred into top matrigel wells (10
5 cancer cells per
well) with WEB2086 (0.1 mM), AG1478 (10 μM) or both.
600 μl of 10% FBS media was added to the bottom of the
chamber and incubated for 48 hours in the invasion assay.
Invasion activity was assessed by the number of cells that
crossed the matrigel and filter membrane. Cell numbers
were counted under a light microscope and presented as
percentage compared to the controls. Experiments were
performed twice, at least three repeats for each treatment.
Assessment of apoptosis and cell cycle
Apoptosis was detected by flow cytometry via the examin-
ation of altered plasma membrane phospholipid packing
by the lipophilic dye Annexin V as described elsewhere.
Briefly, cells were treated with inhibitors and harvested at
24 hours after treatment. The cells were washed twice
with PBS and then resuspended in binding buffer at a con-
centration of 1×10
6 cells/mL according to the manufac-
turer’s instructions. Thereafter, 5 μL of Annexin V-FITC
and 1 μL of propidium iodide were added to 100 μLo fc e l l
suspension and incubated for 20 min at room temperature
in the dark. After adding 400 μL of binding buffer, the la-
beled cells were counted by flow cytometry within 1 hour.
All early apoptotic cells (Annexin V-positive, propidium
iodide -negative), necrotic/late apoptotic cells (double
positive), and living cells (double negative) were detected
using a FACSCalibur flow cytometer and subsequently
analyzed by Cell Quest software. For the cell cycle
analyses, treated cells were fixed in 70% ethanol and
stored at −20°C overnight; the cells were labeled with
propidium iodide (50 μg/ml) and RNase (100 μg/ml)
for 30 min before flow cytometry analysis.
Animals and treatments
Female athymic nu/nu mice (4 to 6 weeks old) were ob-
tained from the Laboratory Animal Center of the Shanghai
Institutes For Biological Sciences of the Chinese Academy
of Sciences. All animal studies were conducted in strict
accordance with protocols approved by the Ethics Com-
mittee for Animal Experimentation of Fudan University. A
total of 2×10
6 CAOV-3 cells was injected into the flanks
of Female athymic nu/nu mice. When established tumors
of approximately 75 mm
3 in Diameter were detected, the
mice were randomly divided into four groups (8 mice/
group), and subjected to various treatments. The PAFR
antagonist WEB2086 was intraperitoneally injected at
5 mg/kg every three days for 2 weeks, and the EGFR in-
hibitor AG1478 was intraperitoneally injected at 10 mg/kg
every three days for 2 weeks. After 3 weeks, all of the mice
were killed, and the tumors were excised and weighed.
The tumor size for the xenografts was determined using a
caliper, and the volume was calculated as=length×
width
2/2, where the width is the smallest measurement
and the length is the longest measurement.
Isobologram analysis
Synergy between WEB2086 and AG1478 was deter-
mined by isobologram analysis using CalcuSyn software
(Biosoft, Cambridge, UK), which analyzes the data from
proliferation assays to determine the interaction between
equipotent drug combinations [26]. The combination
index values <1, =1 and >1 indicate synergy, additivity
and antagonism, respectively.
Statistical analysis
All experiments were performed at least three times.
The data are expressed as the “mean ±SD”. Wherever
appropriate, the data were also subjected to unpaired
two-tailed Student’s t-tests. Differences were considered
significant when P <0.05.
Results
Synergistic interaction between the PAFR antagonist
WEB2086 and the EGFR inhibitor AG1478
As we previously reported that inhibition of PAFR decrased
ovarian cancer cell proliferation and the EGFR inhibition
has shown promise in clinical trials in various types of can-
cers, including ovarian cancer, we asked whether simultan-
eously targeting the two receptors would have synergistic
effects. The inhibitory effects of combined use of the PAFR
antagonist WEB2086 and the EGFR inhibitor AG1478
were tested in two ovarian cancer cell lines, CAOV-3
and SKOV-3 cells. We first examined the basal levels of
PAFR and EGFR in both cells. As shown in Figure 1A
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pression levels of PAFR and EGFR were higher in CAOV-
3 cells compared with that in SKOV-3 cells. To determine
whether WEB2086 and AG1478 exhibit a combined effect
in ovarian cancer cells, we examined the effect of individ-
ual and combination treatment with WEB2086 and
AG1478 after 72-h exposure using the CCK-8 assay. To
ensure that the contributing effects from each drug was
equivalent, IC50 for each was determined and serial dilu-
tions were generated based on the IC50 of each drug
providing 1:1 equipotent WEB2086/AG1478 ratio. We
found that both compounds inhibited cell growth in a
dose-dependent manner in CAOV-3 and SKOV-3 cells
(Figure 1C). To determine whether WEB2086 and AG1478
interact synergistically, isobologram analysis was per-
formed. This analysis provides a CI value that measures
the degree of interaction between two or mor drug,
where a CI <1 and a CI >1 indicates synergism and an-
tagonism, respectively. A CI of 0.49 and 0.58 was indenti-
fied for CAOV-3 and SKOV-3 cells, when the effective
dose (ED) of both agents inhibited cell viability by 50%
(Figure 1D). As shown in Figure 1E, inrespective of high
(See figure on previous page.)
Figure 1 WEB2086 and AG1478 exhibit synergistic cytotoxicity in CAOV-3 and SKOV-3 cells. (A) Under basal growth conditions, whole-cell
extracts obtained from CAOV-3 and SKOV-3 cells were analyzed for EGFR and PAFR. (B) Detection of EGFR and PAFR expression by immunocyto-
chemistry. 1, 2, 3 for CAOV-3 cells and 4, 5, 6 for SKOV-3 cells stained with anti-EGFR antibody, −PAFR antibody, and control IgG, respectively.
(C) Cellular viability was measured by the CCK-8 assay. CAOV-3 and SKOV-3 cells were treated with the indicated concentrations of AG1478 and
WEB2086 for 72 hours. (D) Isobologram analysis of combination WEB2086 with AG1478 used in equipotent concentrations in CAOV-3 and SKOV-3
cells. The line designates the CI where CI=1 (additive effect). CI<1 indicates synergism and CI> 1 represents antagonism. The combination data
points (CI=0.49 for CAOV-3 and CI=0.58 for SKOV-3) calculated by CalcuSyn softwre indicate synergism at ED50. (E) The CI values of combination
WEB2086 and AG1478 at a range of EDs. The CI at ED25, ED50, ED75 and ED90 indicate a synergistic interaction between WEB2086 and AG1478
in CAOV-3 and SKOV-3 cells.
Figure 2 Combination of PAFR and EGFR targeting decreases cell growth and invasion in CAOV-3 and SKOV-3 cell lines. Cells were
treated with WEB2086 (0.1 mM), AG1478 (10 μM), and their combination. (A and B) The percentage of cell survival was measured by the CCK-8
assay 72 hours later. Independent experiments were repeated three times. Columns, means of 3 identical wells of a single representative experiment;
bars, upper 95% confidence interval; **, p <0.005 for comparisons between cells treated with the combined treatment and cells treated with
the single agent. (C and D) Cells were plated in Matrigel invasion chambers and invading cells were counted using light microscopy. Columns, means
of 3 identical wells of a single representative experiment; bars, upper 95% confidence interval; ***, p<0.001 for comparisons between cells treated with
the combined treatment and cells treated with the single agent.
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values was remained below 1, indicating that synergism oc-
curs independently of the equipotency levels of WEB2086
and AG1478. Our results demonstrate that WEB2086 and
AG1478 exhibit a synergistic interaction in ovarian cancer
cells, particularly in CAOV-3 cells.
Combined targeting of PAFR and EGFR inhibits ovarian
cancer cell growth and invasion
To test whether the combined targeting of PAFR and
EGFR resulted in enhanced growth inhibition compared
with the single inhibition, half of the IC50 for each drug
was used to treat ovarian cancer cells, followed by the
CCK-8 assay. As shown in Figure 2A and B, the com-
bined inhibition of both PAFR and EGFR resulted in sig-
nificantly enhanced growth inhibition compared with
either treatment alone over a 72-hour exposure. The re-
sults in CAOV-3 and SKOV-3 cell lines confirmed a
strong inhibitory effect by adding WEB2086 to AG1478.
We previously reported that PAF promots ovarian
cancer cell invasion. In addition to cell growth, we ex-
amined the effects on cell invasion of combined PAFR
and EGFR targeting in ovarian cancer cells. As shown in
Figure 2C and D, although WEB2086 or AG1478 alone
decreased ovarian cancer cell invasion, combined target-
ing significantly enhanced the effect when compared
with either treatment alone.
Combined targeting of PAFR and EGFR increases ovarian
cancer cell apoptosis and G0/G1 arrest
To determine whether the increased antiproliferative
effect was due to increased apoptosis and/or cell cycle
alterations, we examined apoptosis by Annexin V ana-
lysis following WEB2086 and AG1478 treatment. The
number of apoptotic cells was quantified (Figure 3A
and D). As shown in Figure 3B and E, a flow cytometric
analysis of CAOV-3 and SKOV-3 cells revealed that
both WEB2086 and AG1478 increased the number of
apoptotic cells compared to that observed in the un-
treated cells; additionally, the combined targeting signifi-
cantly enhanced CAOV-3 and SKOV-3 cell apoptosis to
71.43% and 78.81%, respectively. These results were con-
firmed by a western blot analysis. Both WEB2086 and
AG1478 were able to induce the cleavage of 113-kDa
Figure 3 Effects of WEB2086 and/or AG1478 on apoptosis in CAOV-3 and SKOV-3 cell lines. Apoptosis was evaluated as described in the
Materials and Methods with Annexin V staining in CAOV-3 and SKOV-3 cells; the cells were treated with WEB2086 (0.1 mM), AG1478 (10 μM), and
their combination. A and D: Representative dot plots illustrating the data near the mean of the groups in B and E. Columns, means of 3 identical
wells of a single representative experiment; bars, upper 95% confidence interval; **, p<0.005 for comparisons between cells treated with the
combined treatment and cells treated with the single agent. C and F: Western blotting analysis of PARP and caspase-3 cleavage following
treatment with WEB2086 alone or with AG1478. Western blotting of β-Actin is included as a loading control.
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ment and induce cleaved caspase-3 in CAOV-3 and
SKOV-3 cells, and the combination of WEB2086 and
AG1478 was accompanied by increased expression of
cleaved PARP and caspase-3 (Figure 3C and F). As shown
in Figure 4, a significant increase in G0/G1-phase cells
after treatment with WEB2086 combined with AG1478
when compared with the single treatment in CAOV-3 and
SKOV-3 cells was observed. This cell cycle delay was also
accompanied by a decreased percentage of S-phase cells.
Identification of intracellular signaling pathways following
the activation of PAFR and EGFR
Enhanced antitumor effects were observed by combined
PAFR and EGFR targeting, which indicates that intracel-
lular signaling pathway crosstalk may occur between the
activated PAFR and EGFR pathways. We next evaluated
the effects of activated PAFR and EGFR on the expression
of selected proteins and their activated forms, which are
known to be important steps in prosurvival and prolifera-
tion pathways in ovarian cancer cells. Because mTOR
pathway regulates cell growth via the phosphorylation of
eukaryotic initiation factor 4E-binding protein 1 (4EBP1)
and ribosomal protein S6 kinase (P70S6K), we assessed
the activation of the mTOR pathway by determining the
phosphorylation of P70S6K and 4EBP1. CAOV-3 cells
were stimulated with PAF (from 0.1 to 1000 nM) or EGF
(from 0.1 to 20 ng/ml), for 24 hours. As shown in Figure 5,
both PAF and EGF evoked increased levels of activated
P70S6K and 4EBP1, without affecting the total amount of
P70S6K and 4EBP1. AKT and ERK phosphorylation was
also increased upon stimulation with PAF and EGF,
respectively. However, the levels of phosphorylated β-
arrestin2 were increased by PAF stimulation, but not by
EGF stimulation in CAOV-3 cells.
Combined targeting of PAFR and EGFR enhances
intracellular signaling pathway inhibition
As we have verified that both activated PAFR and EGFR
can evoke the increased phosphorylation levels of P70S6K,
4EBP1, AKT and MAPK, we next determine whether the
synergistic growth inhibition effects obtained by the com-
bination of the PAFR antagonist WEB2086 and the EGFR
inhibitor AG1478, were due to a more effective inhibition
of intracellular signaling, and we also analysis the effect of
WEB2086 and/or AG1478 treatment on the expression
Figure 4 Effect of WEB2086 and/or AG1478 on the cell cycle in CAOV-3 and SKOV-3 cell lines. The cell cycle was assessed as described in
the Materials and Methods with propidium iodide and RNase staining of CAOV-3 and SKOV-3 cells; the cells were treated with WEB2086 (0.1 mM),
AG1478 (10 μM), and their combination. Aa n dC : Representative dot plots illustrating the data near the mean of the groups in B and D. Columns,
means of 3 identical wells of a single representative experiment; bars, upper 95% confidence interval; *, p<0.05 and **, p<0.005 for comparisons
between cells treated with the combined treatment and cells treated with the single agent.
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analyses were performed on proteins from CAOV-3 and
SKOV-3 cells treated with 10 μM of AG1478, 0.1 mM
WEB2086, or a combination with both, treatment was
conducted for 24 hours. As shown in Figure 6, the com-
bined PAFR and EGFR targeting decreased the phosphor-
ylation levels of EGFR and β-arrestin2 compared with
AG1478 or WEB2086 treatment alone, without affecting
the total amount of EGFR and PAFR. β-arrestin2 has been
shown to be coupled with the activated PAFR and, there-
fore, the phosphorylation of β-arrestin2 indicates the
PAFR activation. Our results suggest that bidirectional
crosstalk may occur between PAFR and EGFR. In addition,
treatment with WEB2086 in combination with AG1478
resulted in a more pronounced decrease in the levels of
protein phosphorylation (p-ERK, p-AKT). The combined
treatment also affected mTOR signaling, as suggested by
the sustained inhibition of P70S6K phosphorylation. These
results suggest that combined therapy targeting PAFR and
EGFR augments antitumor efficacy by inhibiting specific
downstream signaling proteins.
Co-inhibition of PAFR and EGFR significantly inhibits
CAOV-3 tumor xenografts
We finally investigated the in vivo antitumor activity of
combined PAFR and EGFR targeting in nude mice bearing
CAOV-3 cells that were grown subcutaneously as tumor
xenografts. As shown in Figure 7, either AG1478 or
WEB2086 could inhibit tumor growth compared with the
control group (p<0.001). Compared with those two treat-
ments, the combination of AG1478 and WEB2086 led to
the most significant inhibition of tumor growth (p<0.001)
at day 21 post-treatment. The combined treatment of the
two drugs was well tolerated, as no obvious side effects
were observed in the mice treated with AG1478 and/or
WEB2086.
Discussion
The observation that elevated levels of growth factor re-
ceptors are associated with adverse cancer outcomes has
led to the development of approaches that specifically
interrupt these autocrine pathways. The constitutive ac-
tivation of EGFR has been reported in various cancers,
including breast, prostate, and ovarian cancers [27-29].
EGFR monoclonal antibodies and EGFR tyrosine kinase
inhibitors have been approved for use in cancer patients.
Despite these promising preclinical results, the inhib-
ition of EGFR, has resulted in limited antitumor effects
when tested as a monotherapy in clinical settings.
The PAF/PAFR signaling axis has emerged as an im-
portant determinant of aggressive phenotypes in several
malignancies [30]. PAF has been associated with early
malignant transformation in BRCA1 – mutant epithelial
ovarian cells [31], and melanocytic tumorigenesis has
been observed in transgenic mice overexpressing PAFR
[32]. The many effects of PAF in tumors, such as in-
creased vascular permeability, the induction of neoan-
giogenesis, and the activation of metalloproteinases,
Figure 5 Effects on downstream pathways following the activation of PAFR and EGFR in CAOV-3 cells. CAOV-3 cell lysates were
subjected to western blotting of phospho/total- β-arrestin2, phospho/total- P70S6K, phospho/total- ERK, phospho/total- AKT, and phospho/total-
4EBP1 activation following treatment with the indicated concentrations of PAF and EGF for 24 hours. β-Actin was included as a loading control.
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metastasis [33,34]. Recent experiments have shown that
the PAFR antagonist WEB2086 inhibits tumor growth in
a murine melanoma model, improving overall survival
when combined with chemotherapy [35].
Studies on WEB2086 have primarily been performed
with leukemia cells that were induced to undergo differen-
tiation and/or apoptosis. WEB2086 has been proven to
possess the ability to abrogate PAF-mediated signals and
exerts a wide anticancer activity capable of significantly
Figure 7 Effects of the combined PAFR and EGFR targeting on ovarian cancer xenografts. A t h y m i cn u d em i c ew e r ei n j e c t e ds u b c u t a n e o u s l yi n t o
the flank with CAOV-3 cells. (A) Representative photographs of tumors extracted from mice treated with or without WEB2086 (5 mg/kg, i.p., every three
days for 2 weeks) and AG1478 (10 mg/kg, i.p., every three days for 2 weeks). (B) Ovarian cancer volume was determined in mice administered WEB2086
and/or AG1478. The data represent the average (±SD). Student’s t-test was used to compare tumor sizes among the different treatment groups at day
21 following the start of treatment. ***, p<0.001 indicates a statistically significant difference compared to the treatment with the single agent.
Figure 6 Effects on downstream pathways by combined PAFR and EGFR targeting. (A) CAOV-3 cell lysates were harvested 24 h after AG1478
(10 μM), WEB2086 (0.1 mM), or combination treatment. Cell lysates were subjected to immunoblotting with phospho/total -EGFR, phospho-β- arrestin2,
PAFR, phospho/total-P70S6K, phospho/total-AKT, phospho/total-ERK. β-Actin was included as a loading control. (B) SKOV-3 cell lysates were harvested
24 h after AG1478 (10 μM), WEB2086 (0.1 mM), or combination treatment. Cell lysates were subjected to immunoblotting with the antibodies used in A.
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ferent histogeneses and with a much higher efficacy than
in normal cells. In addition, earlier experiments from our
group have shown that the activation of PAFR has pleio-
tropic effects on tyrosine phospho-EGFR/Src/Paxillin in
ovarian cancer. Therefore, we hypothesized that there
would be crosstalk between the PAFR and EGFR path-
ways, which may be one of reasons for the resistance of
cancer cells to drugs, and that the combined targeting of
PAFR and EGFR would synergistically inhibit ovarian can-
cer progression.
In this study, we evaluated for the first time the antitu-
mor effects of PAFR and EGFR targeting strategies in
ovarian cancer cell lines using the PAFR antagonist
WEB2086 and EGFR inhibitor AG1478. In our in vitro
and in vivo studies, we demonstrated that EGFR and
PAFR were overexpressed in ovarian cancer cell lines,
which led us to speculate that simultaneously targeting
PAFR and EGFR may be a more effective therapeutic
strategy than targeting either signaling pathway alone.
Our results show that the combined inhibition of PAFR
and EGFR additively inhibited ovarian cancer progres-
sion. The decrease in viable tumor cells resulted from
the induction of apoptosis, G0/G1 cell cycle arrest, and
the reduction of cells in S phase.
However, the mechanisms responsible for the synergis-
tic effects of targeting both PAFR and EGFR are not
completely understood. If activated PAFR signaling acts
through the EGFR signaling pathway, then EGFR target-
ing alone should achieve the same effect as combined
targeting. The enhanced antitumor effects observed
when targeting both receptors in combination suggest
that EGFR-independent signaling pathways are also acti-
vated by PAF. Our results show that phosphorylation
levels of P70S6K, 4EBP1, AKT, and MAPK were increased
when cells were stimulated with either PAF or EGF in dif-
ferent doses (as shown in Figure 5). These results suggest
that crosstalk exists between intracullelar signaling path-
ways following activation of PAFR and EGFR. With the
combined treatment of WEB2086 and AG1478, the phos-
phorylation levels of these proteins were more reduced
than with either treatment alone. Taken together, the ex-
pression of these proteins was affected by both EGFR-
dependent and EGFR- independent pathways. It has been
reported that after specific agonist stimulation, G protein-
coupled receptors (GPCRs) use multifunctional adaptor
proteins such as β-arrestins to activate many substrates in
cellular pathways [36,37]. Thus β-arrestin acts as a bifunc-
tional cellular mediator; that is, it not only terminates
G protein signaling but also functions as a scaffold for
transduction of the G protein signal [38]. We also observed
β-arrestin2 protein was modulated by PAFR, but not EGFR,
suggesting that the inhibition of the EGFR pathway alone
cannot effectively suppress ovarian cancer progression.
Our previous study reported that the PAFR ligand PAF
can activate phospho-EGFR and induce proliferation and
invasion in ovarian cancer, and the results of the present
study show that the PAFR antagonist WEB2086 can in-
hibit EGFR activation. It is apparent that the persistent
activation of PAFR in the face of EGFR blockade still
contributes to tumor growth and resistance. Identifica-
tion of the proteins that are induced by PAF, in the pres-
ence or absence of EGFR inhibition, will determine the
critical pathways to be targeted in combination with
EGFR blockade. Further research is underway to eluci-
date the exact mechanism involved in this process to
optimize ovarian cancer treatment regimens.
Conclusions
Taken together, both in vitro and in vivo analyse suggest
that PAFR and EGFR play an important role in the sus-
tained growth, survival, and invasion of ovarian cancer
cells. The combined usage of selective inhibitors of PAFR
and EGFR, such as WEB2086 and AG1478, represents a
promising strategy for the treatment of ovarian cancer.
This novel combination of drugs offers a new choice for
the current platinum- based regimens, but it is critical to
evaluate the profile of PAFR and EGFR expression in ovar-
ian cancer patients before the strategy is applied in the
clinical setting.
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